List of bibliographic references
Number of relevant bibliographic references: 7.
| Ident. | Authors (with country if any) | Title |
|---|
| 000556 (2016) |
Jeffrey H. Lipton [Canada] ; Charles Chuah [Singapour] ; Agnès Guerci-Bresler [France] ; Gianantonio Rosti [Italie] ; David Simpson [Nouvelle-Zélande] ; Sarit Assouline [Canada] ; Gabriel Etienne [France] ; Franck E. Nicolini [France] ; Philipp Le Coutre [Allemagne] ; Richard E. Clark [Royaume-Uni] ; Leif Stenke [Suède] ; David Andorsky [États-Unis] ; Vivian Oehler [États-Unis] ; Stephanie Lustgarten [États-Unis] ; Victor M. Rivera [États-Unis] ; Timothy Clackson [États-Unis] ; Frank G. Haluska [États-Unis] ; Michele Baccarani [Italie] ; Jorge E. Cortes [États-Unis] ; François Guilhot [France] ; Andreas Hochhaus [Allemagne] ; Timothy Hughes [Australie] ; Hagop M. Kantarjian [États-Unis] ; Neil P. Shah [États-Unis] ; Moshe Talpaz [États-Unis] ; Michael W. Deininger [États-Unis] | Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. |
| 000B88 (2014) |
Timothy P. Hughes [Australie] ; Jeffrey H. Lipton [Canada] ; Nelson Spector [Brésil] ; Francisco Cervantes [Espagne] ; Ricardo Pasquini [Brésil] ; Nelma Cristina D. Clementino [Brésil] ; Pedro Enrique Dorlhiac Llacer [Brésil] ; Anthony P. Schwarer [Australie] ; Francois-Xavier Mahon [France] ; Delphine Rea [France] ; Susan Branford [Australie] ; Das Purkayastha ; Latonya Collins ; Tomasz Szczudlo ; Brian Leber [Canada] | Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. |
| 000E08 (2013) |
Michele Baccarani [Italie] ; Michael W. Deininger [États-Unis] ; Gianantonio Rosti [Italie] ; Andreas Hochhaus [Allemagne] ; Simona Soverini [Italie] ; Jane F. Apperley [Royaume-Uni] ; Francisco Cervantes [Espagne] ; Richard E. Clark [Royaume-Uni] ; Jorge E. Cortes [États-Unis] ; François Guilhot [France] ; Henrik Hjorth-Hansen [Norvège] ; Timothy P. Hughes [Australie] ; Hagop M. Kantarjian [États-Unis] ; Dong-Wook Kim [Corée du Sud] ; Richard A. Larson [États-Unis] ; Jeffrey H. Lipton [Canada] ; François-Xavier Mahon [France] ; Giovanni Martinelli [Italie] ; Jiri Mayer [République tchèque] ; Martin C. Müller [Allemagne] ; Dietger Niederwieser [Allemagne] ; Fabrizio Pane [Italie] ; Jerald P. Radich [États-Unis] ; Philippe Rousselot [France] ; Giuseppe Saglio [Italie] ; Susanne Sau Ele [Allemagne] ; Charles Schiffer [États-Unis] ; Richard Silver [États-Unis] ; Bengt Simonsson [Suède] ; Juan-Luis Steegmann [Espagne] ; John M. Goldman [Royaume-Uni] ; Rüdiger Hehlmann [Allemagne] | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 |
| 001690 (2009) |
Jane F. Apperley [Royaume-Uni, États-Unis, Corée du Sud, France, Italie, Argentine, Allemagne, Suisse, Brésil, Canada, Autriche, Australie] ; Jorge E. Cortes ; Dong-Wook Kim ; Lydia Roy ; Gail J. Roboz ; Gianantonio Rosti ; Eduardo O. Bullorsky ; Elisabetta Abruzzese ; Andreas Hochhaus ; Dominik Heim ; Carmino A. De Souza ; Richard A. Larson ; Jeffrey H. Lipton ; H. Jean Khoury ; Hyeoung-Joon Kim ; Christian Sillaber ; Timothy P. Hughes ; Philipp Erben ; Jan Van Tornout ; Richard M. Stone | Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial |
| 001906 (2007) |
Francois Guilhot [France] ; Jane Apperley [Royaume-Uni] ; Dong-Wook Kim [Corée du Sud] ; Eduardo O. Bullorsky [Argentine] ; Michele Baccarani [Italie] ; Gail J. Roboz [États-Unis] ; Sergio Amadori [Italie] ; Carmino A. De Souza [Brésil] ; Jeffrey H. Lipton [Canada] ; Andreas Hochhaus [Allemagne] ; Dominik Heim [Suisse] ; Richard A. Larson [États-Unis] ; Susan Branford [Australie] ; Martin C. Muller [Allemagne] ; Prasheen Agarwal [États-Unis] ; Ashwin Gollerkeri [États-Unis] ; Moshe Talpaz [États-Unis] ; Stephen O'Brien [États-Unis] | Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Commentary |
| 001907 (2007) |
Jacob M. Rowe [États-Unis] ; Andreas Hochhaus [Allemagne] ; Hagop M. Kantarjian [États-Unis] ; Michele Baccarani [Italie] ; Jeffrey H. Lipton [Canada] ; Jane F. Apperley [Royaume-Uni] ; Brian J. Druker [États-Unis] ; Thierry Facon [France] ; Stuart L. Goldberg [États-Unis] ; Francisco Cervantes [Espagne] ; Dietger Niederwieser [Allemagne] ; Richard T. Silver [États-Unis] ; Richard M. Stone [États-Unis] ; Timothy P. Hughes [Australie] ; Martin C. Muller [Allemagne] ; Rana Ezzeddine [États-Unis] ; Athena M. Countouriotis [États-Unis] ; Neil P. Shah [États-Unis] | Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Commentary |
| 001982 (2006) |
Timothy Hughes [Australie, États-Unis, Allemagne, Royaume-Uni, Italie, France, Canada] ; Michael Deininger ; Andreas Hochhaus ; Susan Branford ; Jerald Radich ; Jaspal Kaeda ; Michele Baccarani ; Jorge Cortes ; Nicholas C. P. Cross ; Brian J. Druker ; Jean Gabert ; David Grimwade ; Rüdiger Hehlmann ; Suzanne Kamel-Reid ; Jeffrey H. Lipton ; Janina Longtine ; Giovanni Martinelli ; Giuseppe Saglio ; Simona Soverini ; Wendy Stock ; John M. Goldman | Monitoring CML patients responding to treatment with tyrosine kinase inhibitors : review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Protein-tyrosine kinase |
| 3 | Antineoplastic agent |
| 3 | Chronic myelocytic leukemia |
| 3 | Enzyme inhibitor |
| 3 | Imatinib |
| 2 | Adult |
| 2 | Aged |
| 2 | Aged, 80 and over |
| 2 | Cytogenetics |
| 2 | Female |
| 2 | Fusion Proteins, bcr-abl (genetics) |
| 2 | Human |
| 2 | Humans |
| 2 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy) |
| 2 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics) |
| 2 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (pathology) |
| 2 | Male |
| 2 | Middle Aged |
| 2 | Treatment |
| 1 | Adolescent |
| 1 | Antineoplastic Combined Chemotherapy Protocols (administration & dosage) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 1 | Benzamides (administration & dosage) |
| 1 | Benzamides (adverse effects) |
| 1 | Cancerology |
| 1 | Chronic |
| 1 | Chronic myelogenous leukemia |
| 1 | Clinical trial |
| 1 | Dasatinib |
| 1 | Disease-Free Survival |
| 1 | Drug Substitution |
| 1 | Drug-Related Side Effects and Adverse Reactions (classification) |
| 1 | Drug-Related Side Effects and Adverse Reactions (pathology) |
| 1 | Fusion Proteins, bcr-abl (antagonists & inhibitors) |
| 1 | Fusion Proteins, bcr-abl (metabolism) |
| 1 | Fusion protein |
| 1 | Gene expression |
| 1 | Hematology |
| 1 | Hybrid gene |
| 1 | Imatinib Mesylate |
| 1 | Imatinib Mesylate (administration & dosage) |
| 1 | Imatinib Mesylate (adverse effects) |
| 1 | Imidazoles (administration & dosage) |
| 1 | Imidazoles (adverse effects) |
| 1 | Kaplan-Meier Estimate |
| 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (enzymology) |
| 1 | Minimal residual disease |
| 1 | Philadelphia Chromosome (drug effects) |
| 1 | Philadelphia chromosome |
| 1 | Piperazines (administration & dosage) |
| 1 | Piperazines (adverse effects) |
| 1 | Polymerase chain reaction |
| 1 | Protein Kinase Inhibitors (administration & dosage) |
| 1 | Protein Kinase Inhibitors (adverse effects) |
| 1 | Protein inhibitor |
| 1 | Pyridazines (administration & dosage) |
| 1 | Pyridazines (adverse effects) |
| 1 | Pyrimidines (administration & dosage) |
| 1 | Pyrimidines (adverse effects) |
| 1 | Real time |
| 1 | Review |
| 1 | Surveillance |
| 1 | Time Factors |
| 1 | Treatment Outcome |
| 1 | Treatment resistance |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "Jeffrey H. Lipton"
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i \
-Sk "Jeffrey H. Lipton" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Canada
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Jeffrey H. Lipton
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
